Tag Archives: palbociclib

June, 2018

December, 2017

April, 2017

March, 2016

  • 3 March

    FDA Approves New Indication for AstraZeneca’s Faslodex

    AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved a new indication expanding the use of FASLODEX® (fulvestrant) to include use in combination with palbociclib. The combination use is for the treatment of women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) …

February, 2016

  • 22 February

    FDA Expands Approval of Pfizer’s Ibrance in Metastatic Breast Cancer

    Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication expanding the use of IBRANCE® (palbociclib) 125mg capsules, Pfizer’s metastatic breast cancer therapy. Now IBRANCE also is approved for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) …

January, 2016

October, 2015

February, 2015

  • 4 February

    Pfizer’s Breast Cancer Drug Receives Accelerated Approval from the FDA

    Federal health regulators have provided an early approval to Pfizer Inc.’s Breakthrough breast cancer drug palbociclib. The company announced that the US Food and Drug Administration (FDA) has granted accelerated approval of Ibrance (palbociclib) in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth …

January, 2015

  • 8 January

    Pfizer Provides Update on its Breast Cancer Candidate

    Today, Pfizer Inc. announced that it is in discussion with the US Food and Drug Administration (FDA), regarding its potential blockbuster breast cancer drug palbociclib. According to the company, it expects to get a final decision from the agency by April 13. Pfizer said that the FDA is not requiring …